- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer immune therapy for lymphoid malignancies: recent advances
Authors
Keywords
Immunotherapy, Lymphoma, Leukemia, Multiple myeloma, CAR-T cells, Bispecific antibodies, Vaccination therapy, Immune checkpoint inhibitors
Journal
Seminars in Immunopathology
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-13
DOI
10.1007/s00281-018-0696-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
- (2018) Myrna R. Nahas et al. BLOOD REVIEWS
- Bispecific antibodies in haematological malignancies
- (2018) Andreas Viardot et al. CANCER TREATMENT REVIEWS
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
- (2017) Frank (Xiaohu) Fan et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint inhibitors in hematological malignancies
- (2017) Chi Young Ok et al. Journal of Hematology & Oncology
- Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
- (2017) Matthew J. Pianko et al. LEUKEMIA & LYMPHOMA
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapies for lymphoma
- (2017) Jennifer N. Brudno et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
- (2016) A. Viardot et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2016) Arend von Stackelberg et al. JOURNAL OF CLINICAL ONCOLOGY
- The elephant in the room: Facilitating conversations about advanced cancer between patients and their spouses.
- (2016) Laura S. Porter et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Differentiation stage of myeloma plasma cells: biological and clinical significance
- (2016) B Paiva et al. LEUKEMIA
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
- (2016) H Suen et al. LEUKEMIA
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
- (2015) S Yousef et al. Blood Cancer Journal
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
- (2014) Ronald Levy et al. JOURNAL OF CLINICAL ONCOLOGY
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
- (2013) J. Rosenblatt et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells
- (2013) Ute E. Burkhardt et al. JOURNAL OF CLINICAL INVESTIGATION
- Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
- (2011) Stephen J. Schuster et al. JOURNAL OF CLINICAL ONCOLOGY
- Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
- (2010) J. Rosenblatt et al. BLOOD
- Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
- (2009) Martha Q. Lacy et al. AMERICAN JOURNAL OF HEMATOLOGY
- Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
- (2009) Arnold Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started